US FDA grants orphan drug status to AstraZeneca’s asthma drug Fasenra
EoE, also known as allergic oesophagitis, is an allergic inflammation of the esophagus that involves a form of white blood cell, eosinophils
AstraZeneca announced that the US Food and Drug Administration has granted orphan drug status to its severe asthma drug, Fasenra, to treat eosinophilic oesophagitis (EoE).
EoE, also known as allergic oesophagitis, is an allergic inflammation of the esophagus that involves a form of white blood cell, eosinophils.
AstraZeneca also separately said it met the main goal for its late-stage ETHOS trial for triple-drug therapy Breztri Aerosphere, formerly known as PT010, to treat moderate to very severe chronic obstructive pulmonary disease (COPD).